Monocyte/macrophage activation by immunostimulators role in cancer therapy

Clinical Immunotherapeutics

Volumn 5, Issue 4, 1996, Pages 294-308

  Hennemann, Burkhard ^a   Andreesen, Reinhard ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; COLONY STIMULATING FACTOR 1; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; LIPOPOLYSACCHARIDE; MURAMYL TRIPEPTIDE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CELL ACTIVITY; CELL DIFFERENTIATION; CLINICAL TRIAL; CYTOTOXICITY; GENE TRANSFER; HUMAN; IMMUNOMODULATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029931847     PISSN: 11727039     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03259328     Document Type: Article

References (135)

1. van Furth R, Cell biology of mononuclear phagocytes. In: van Furth R, editor. Hematopoietic growth factors and mononuclear phagocytes. Basel: Karger, 1993
2. Andreesen R, Osterholz J, Bross KJ, et al, Cytotoxic effector cell function at different stages of human monocyte-macrophage maturation. Cancer Res 1983; 43: 5931-6
3. Scheibenbogen C, Zenke G, Faggs B, et al, Secretion of colonystimulation factor for macrophages (M-CSF) and granulocytes/macrophages (GM-CSF) is developmentally regulated. In: Freund M, Linke H, Weite K, editors. Human macrophages and cytokines in hematopoiesis, oncology and AIDS. Berlin, Heidelberg: Springer Verlag, 1990
4. Lavnikova N, Drapier JC, Laskin DL, A single exogenous stimulus activates resident rat macrophages for nitric oxide production and tumor cytotoxicity. J Leukoc Biol 1993; 54:322-8
5. Andreesen R, Scheibenbogen C, Kreutz M, et al, Regulation of neopterin secretion during human monocyte to macrophage differentiation in vitro. Pteridines 1990: 2: 59-61
6. Scheibenbogen C, Andreesen R, Developmental regulation of the cytokine repertoire in human macrophages: IL-1, IL-6, TNF-a and M-CSF. J Leukoc Biol 1991; 50: 35-42
7. Schwamberger G, Flesch I, Ferber E, Characterisation and purification of a high molecular weight tumoricidal activity secreted by murine bone marrow macrophages. Int Immunol 1992; 4: 253-64
8. Somers SD, Johnson WJ, Actams DO, Destruction of tumor cells by macrophages: mechanisms of recognition and lysis and their regulation. In: Herberman RB, editor. Cancer immunology: innovative approaches to therapy. Boston, London: Martinus Nijhoff Publishers, 1986
9. Petit JF, Phan-Bich L, Lemaire G, et al, During their differentiation into macrophages human monocytes acquire cytostatic activity independent of nitric oxide and TNF-cx. Res Immunol 1993; 144: 265-98
10. Charak BS, Agah R, Mazumder A, Granulocyte-macrophage colony-stimulating factor-induced antibody-dependent cellular cytotoxicity in bone marrow macrophages: application in bone marrow transplantation. Blood 1993; 81(12): 3474-9
11. Munn DH, Cheung NK. Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. J Exp Med 1989; 170: 511-26
12. Currie GA, Activated macrophages kill tumor cells by releasing arginase. Nature 1978; 273: 758-9
13. Bentley C, Bitter-Suermann D, Hadding U, et al, In vitro synthesis of factor B of the alternative pathway of complement activation by mouse peritoneal macrophages. Eur J Immunol 1976; 6: 393-8
14. Goodman MG, Weigle WO, Hugli TE, Inability of the C3a anaphylaxatoxin to promote cellular lysis. Nature 1980; 283: 78-80
15. Gordon S, Lysozyme and plasminogen activator - constitutive and induced secretory products of mononuclear phagocytes. In: van Furth R, editor. Mononuclear phagocytes. The Hague: Nijhoff Publishers, 1980: 1273
16. Johnson WI, Weiel JE, Actams DO, The relationship between secretion of a novel cytolytic protease and macrophage-mediated tumor cytotoxicity. In: Herbermann R, editor. Natural cell-mediated immunity II. New York: Academic Press, 1982: 949-54
17. Fomsgaard A, Worsaae H, Bendtzen K, Detection of tumor necrosis factor from lipopolysaccharide-stimulated human mononuclear cells by enzyme-linked immunoabsorbent assay and cytotoxicity bioassay. Scand J Immunol 1988; 27: 143-7
18. Metzger Z, Hoffeld JT, Oppenheim JJ, Macrophage-mediated suppression: I. Evidence for participation of both hydrogen peroxide and prostaglandins in suppression of murine lymphocyte proliferation. J Immunol 1980; 124: 983-8
19. 2 and CF can interact synergistically in effecting cytolysis of neoplastic targets. J Immunol 1973; 127: 120-2
20. Rosztoczy I, Content J, The effect of various cytokines on interleukin-6 and interferon-a synthesis in human peripheral blood mononuclear cells. J Interferon Res 1990; 10: 637-45
21. Meyernik D, Haq A, Rinehard JJ, Interleukin-1 secretion by human monocytes and macrophages. J Leukoc Biol 1984; 36: 551-7
22. Davies P, Page RC, Allison AC, Changes in cellular enzyme levels and extracellular release of lysosomal acid hydrolases in macrophages exposed to group A streptococcal wall substance. J Exp Med 1974; 139: 1262-82
23. Gordon S, Todd J, Cohn ZA. In vitro synthesis and secretion of lysozyme by mononuclear phagocytes. J ExpMed 1974; 139: 1228-48
24. Drysdale BE, Zachaehutz CM, Shin HS, Mechanism of macrophage-mediated cytotoxicity: production of a soluble cytotoxic factor. J Immunol 1983; 131: 2362-7
25. Stadecker MJ, Unanue ER. The regulation of thymidine secretion by macrophages. J Immunol 1979: 123: 568-71
26. Kreutz M, Andreesen R, Krause S, et al. 1,25-Dihydroxyvitamin DT production and vitamin Di receptor expression are developmentally regulated during differentiation of human monocytes into macrophages. Blood 1993; 82: 1300-7
27. Actams DO, Hamilton TA. The cell biology of macrophage aclivation. Annu Rev Immunol 1984; 2: 283-318
28. SchwambergerG, Flesch I, FerberE.Tumoricidal effector molecules of murine macrophages. Pathobiology 1991; 59: 248-53
29. Fidler U, Kleinermann ES, Lymphokine-activated human blood monocytes destroy tumor cells but not normal cells under cocultivation conditions. J Clin Oncol 1984; 2: 937-43
30. Shimizu H, Wyalt K, Knowles RD, et al, Human monocytes selectively bind to cells expressing the tumorigenic phenotype. Cancer Immunol Immunother 1989: 28: 185-92
31. Fidler IJ, Recognition and destruction of target cells by tumoricidal macrophages. Isr J Med Sei 1978; 14: 177-92
32. Lee AM, Vadhan-Raj S, Hamilton RF, et al. The in vivo effects of rhIL-la therapy on human monocyte activity. J Leukoc Biol 1993:54:314-21
33. Andreesen R, Osterholz J, Luckenbach GA, et al, Tumor cytotoxicity of human macrophages after incubation with synthetic analogues of 2-lysophosphatidylcholine. J Natl Cancer Inst 1984:72:53-9
34. Saiki l, Fidler U. Synergistic activation by recombinant mouse interferon-gamma and muramyl dipeptide of tumoricidal properties in mouse macrophages. J Immunol 1985: 135: 684-8
35. Nathan C, Cohn ZA. Role of oxygen-dependent mechanisms in antibody-induced lysis of tumor cells by activated macrophages. J Exp Med 1980; 152: 198-208
36. Koren HS, Andreson SJ, Actams DO. Studies on the antibodydependent cell-mediated cytotoxicity ( ADCC) of thiaglycollate-stimulated and BCG-activated peritoneal macrophages. Cell Immunol 1981; 57: 51-61
37. Koren HS, Meltzer MS, Actams DO, The ADCC capacity of macrophages from C3H/HEJ and A/J mice can be augmented by BCG. J Immunol 1981: 126: 1013-15
38. Steplewski Z, Herlyn D, Maul G. et al. Hypothesis: macrophages as effector cells of human tumor destruction mediated by monoclonal antibodies. Hybridoma 1983: 2: 1-5
39. Langlois AJ, Matthews TJ, Roloson GJ, et al. Immunologie control of the ascites form of murine adenocarcinoma 755: V. antibody-directed macrophages mediate tumor cell destruction. J (mmunol 1981; 126:2337-41
40. Johnson WJ, Steplewski Z, Matthews TJ, et al, Cytolvtic interactions between murine macrophages, tumor cells and monoclonal antibodies: characterization of lytic conditions and requirements for effector activation. J Immunol 1986; 136: 4704-13
41. Nathan CF, Silverstein SC, Bruckner LH, et al. Extracellular cytolysis by activated macrophages and granulocytes: II. Hydrogen peroxide as a mediator of cytotoxicity. J Exp Med 1979; 149: 100-13
42. Johnson WJ, Bolognesi DP, Actams DO. Antibody dependent cytolysis (ADCC) of tumor cells by activated murine macro-phages is a two step process: quantification of target binding and subsequent target lysis. Cell Immunol 1984; 83: 170-80
43. Munn DH, Cheung NK, Phagocytosis of tumor cells by human monocytes cultured in recombinant macrophage colonystimulating factor. J Exp Med 1990; 172: 231-7
44. Van de Loosdrecht AA, Ossenkoppele GJ, Beelen RHJ, et al. Maturation-dependent susceptibility to monocyte-mediated cytotoxicity in acute myeloid leukemia. Leukemia 1994; 8: 1392-400 '
45. Van der Bosch J, Müller S, Horn D. et al. Density-dependent tumor cell death and reversible cell cycle arrest: mutually exclusive modes of monocyte-mediated growth control. Exp Cell Res 1990; 187: 185-92
46. WithworthPW, Pak CP, EsgroJ, et al. Macrophages and cancer. Cancer Metastasis Rev 1990: 8:319-51
47. Berg JW, Inflammation and prognosis in breast cancer. Cancer 1959; 12: 714-5
48. Dizon Q, Southam CM, Abnormal cellular response to skin abrasions in cancer patients. Cancer 1963: 16: 1288-92
49. Eccles SA, Alexander P. Macrophage content of tumors in relation to metastatic spread and host immune reaction. Nature 1974: 250: 667-9
50. Russell SW, Mclntosh AT, Macrophages isolated from regressing Moloney sarcomas are more cytotoxic than recovered from progressing sarcomas. Nature 1977; 268: 69-71
51. Fauve RM, Hevin B. Jacob H. et al. Antiinflammatory effects of murine malisnant cells. Proc Natl Acad Sei USA 1974: 7l : 4072-4
52. Cianciolo GJ, Antiinflammatory effects of neoplasms. Res Inimunol 1993; 144: 268-71
53. Lindvall M, Sjögren HO. Inhibition of rat yolk sac tumor growth in vivo by a monoclonal antibody to the retroviral molecule P15E. Cancerlmmunol Immunother 1991 ; 33: 21 -7
54. Schultz RM, Stoychkov JN, Pavlidis N, et al, Role of E-type prostaglandins in the regulation of interferon-treated macrophage cytotoxic activity. J Reticuloendothel Soc 1979: 26: 93-102
55. Eeung KH, Fischer DG, Koren HS. Erythromyeloid tumor cells (K562) induce PGE synthesis in human peripheral blood monocytes. J Immunol 1983; 131: 445-9
56. Van Damme J, Proost P, Eenaerts JP, et al. Structural and functional identification of two human, tumor-derived monocyte chemotactic proteins (MCP-2 and MCP-3) belonging to the chemokine family. J Exp Med 1992: 176: 59-69
57. Mantovani A, Bottazzi B, Colotta F, et al. The origin and function of tumor-associated macrophages. Immunol Today 1992: 13: 265-70
58. Assoian RK, Fleurdelys BE, Stevenson HC, et al. Expression and secretion of type B transforming growth factor by activated human macrophages. Proc Natl Acad Sei USA 1987; 84: 6020-4
59. Polverini PJ, Eeibovich SJ. Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Eab Invest 1984; 51: 635-42
60. Andreesen R, Kreutz M. Differentiation of human monocytes in vitro: a model of macrophage ontogeny. In: Fusenig NE. Graf H, editors. Cell culture in pharmaceutical research. Berlin: Springer Verlag, 1994: 9-27
61. Andreesen R, Bross KJ, Osterholz J, et al. Human macrophage maturation and heterogeneity: analysis with a newly generated set of monoclonal antibodies to differentiation antigens. Blood 1986:67: 1257-64
62. Andreesen R, Brugger W, Gadd S, et al. Activation of human monocyte-derived macrophages cultured on teflon: response to interferon-gamma during terminal maturation in vitro. Immunobiology 1988; 177: 186-98
63. Fidler U, Targeting of immunomodulators to mononuclear phagocytes for therapy of cancer. Adv Drug Delivery Rev 1988; 1:69-106
64. Tanguay S, Bucana CD, Wilson MR, et al, In vivo modulation of macrophage tumoricidal activity by oral administration of the liposome-encapsulated macrophage activator CGP19835A. Cancer Res 1994; 54: 5882-8
65. Kleinermann ES, Murray JL, Snyder JS, et al, Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Res 1989; 49: 4665-70
66. Kleinermann ES, Raymond AK, Bucana CD, et al, Unique histological changes in lung métastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Immunol Immunother 1992; 34: 211-20
67. Brown TD, Koeller J, Beaugher K, et al, A phase I clinical trial of recombinant DNA gamma-interferon. J Clin Oncol 1987; 5: 790-8
68. Aulitzki W, Gastl G, Aulitzki WE, et al, Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma. J Clin Oncol 1989; 7: 1875-84
69. Hofmockel G, Wirth MP, Heimbach D, et al, Results of low dosage cyclic interferon-gamma therapy of metastatic renal cell carcinoma. Urologie 1993; 32: 290-4
70. Ellerhorst JA, Kilbourn RG, Amato RJ, et al, Phase II trial of low dose gamma-interferon in metastatic renal cell carcinoma. J Urol 1994; 152:841-5
71. Garnick MB, Reich SD, Maxwell B, et al, Phase I/II study of recombinant interferon gamma in advanced renal cell carcinoma. J Urol 1988; 139:251-5
72. Colombo N, Peccatori E, Paganin C, et al, Anti-tumor and immunomodulatory activity of intraperitoneal IFN-gamma in ovarian carcinoma patients with minimal residual tumor after chemotherapy. Int J Cancer 1992; 51: 42-6
73. Chen JT, Hasumi K, Masubuchi K, Maintenance of the activation of peritoneal macrophages in patients with ovarian cancer by sizofiran and recombinant interferon-gamma. Biotherapy 1992; 5: 137-43
74. Greiner JW, Guadagni F, Goldstein D, et al, Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells. J Clin Oncol 1992; 10: 735-46
75. Pujade-Lauraine E, Guastella JP, Colombo N, et al, Interferongamma par voie intrapéritonéale: un complément efficace de la chimiothérapie des cancers de l'ovaire. Apropos d'une étude européenne de 108 patientes. Bull Cancer 1993; 80: 163-70
76. Jaffe HA, Buhl R, Mastangeli A, et al, Local activation of mononuclear phagocytes by delivery of an aerosol of recombinant interferon-gamma to the human lung. J Clin Invest 1991; 88: 297-302
77. Boutin C, Nussbaum E, Monnet I, et al, Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer 1994; 74: 2460-7
78. Jett JR, Maksymiuk AW, Su JQ, et al, Phase III trial of recombinant interferon gamma in complete responders with smallcell lung cancer. J Clin Oncol 1994; 12: 2321-6
79. Silagi S, Dutkowski R, Schaeffer A, Eradication of mouse melanoma by combined treatment with recombinant human interleukin 2 and recombinant murine Interferon gamma. Int J Cancer 1988; 41: 315-22
80. Redman BG, Flaherty L, Chou TH, el al, A phase I trial of recombinant interleukin-2 combined with recombinant interferon-gamma in patients with cancer. J Clin Oncol 1990; 8: 1269-76
81. Viens P, Biaise D, Stoppa AM, et al, Interleukin-2 in association with increasing doses of interferon-gamma in patients with advanced cancer. J Immunother 1992; 11:218-24
82. Escudier B, Farace F, Angevin E, et al, Combination of interleukin-2 and gamma Interferon in metastatic renal cell carcinoma. Eur J Cancer 1993; 29; 724-8
83. Czarniecki CW, Fennie CW, Powers DB, et al, Synergistic antiviral and antiproliferative activities of E. co/i derived human alpha, beta, and gamma interferon. J Virol 1984; 49: 490-6
84. Hubbell HR, Craft JA, Leibowitz PH, et al, Synergistic antiproliferative effect of recombinant alpha-interferons with recombinant gamma-interferons. J Biol Response Mod 1987; 6: 141-53
85. Nishisaka N, Yoshihara H, Nakatani T, et al, Clinical study of immunotherapy with interferon alpha and gamma in metastatic renal cell carcinoma. Nippon Hinyokika Gakkai Zasshi 1993; 84: 1987-93
86. De Mulder PH, Debruyne FM, Franssen MP, et al, Phase 1/11 study of recombinant interferon alpha and gamma in advanced progressive renal-cell carcinoma. Cancer Immunol Immunother 1990; 31: 321-4
87. De Mulder PH, Oosterhof G, Bouffioux C, et al, EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma: the EORTC Genitourinary Group. Br J Cancer 1995; 71: 371-5
88. Coley WB, The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. AmJMedSci 1893; 105:487-511
89. Mitchie HR, Manogue KR, Springs DR, et al, Detection of circulating tumor necrosis factor after endotoxin administration. NEnglJMed 1988; 318; 1481-6
90. Fong Y, Moldawer LL, Marano M, et al, Endotoxemia elicits increased circulating beta2-IFN/IL-6 in man. J Immunol 1989; 142:2321-4
91. Martich GD, Danner RL, Ceska M, et al, Detection of interleukin-8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents. JExpMed 1991; 173: 1021-4
92. Sack TH, Seligman A, Chemical alteration of polysaccharide from Serralia marcescens: II. Effects of lipopolysaccharide in patients with malignant tumors. J Natl Cancer Inst 1948; 9: 19-34
93. Vosika GJ, Barr C, Gilsbertson D, Phase I study of intravenous modified lipid A. Cancer Immunol Immunother 1984; 18: 107-12
94. Engelhardt R, Mackensen A, Galanos C, et al, Biological response to intravenously administered endotoxin in patients with advanced cancer. J Biol Response Mod 1990; 9: 480-91
95. Engelhardt R, Mackensen A, Galanos C, Phase I trial of intravenously administered endotoxin (Salmonella abortus equi) in cancer patients. Cancer Res 1991 ; 51: 2524-30
96. Hume DA, Pavli P, Donahue RE, et al, The effect of human recombinant macrophage colony-stimulating factor (CSF-1 ) on the murine mononuclear phagocyte system in vivo. J Immunol 1988; 141:3405-9
97. Garnick MB, Stoudemire JB, Preclinical and clinical evaluation of recombinant human macrophage colony-stimulating factor (rhM-CSF). Int J Cell Cloning 1990; 8 Suppl. 1: 356-73
98. Bajorin DF, Cheung NKV, Houghton AN, Macrophage colonystimulating factor: biological effects and potential applications for cancer therapy. Semin Hematol 1991; 28 Suppl.: 42-8
99. Sanda MG, Yang JC, Topalian SL. et al. Intravenous administration of recombinant human macrophage colony-stimulating factor (M-CSF) to patients with metastatic cancer: a phase I .study. J Clin Oncol 1992: 10: 1643-9
100. Weiner LM, Li W, Holmes M, et al, Phase I trial of recombinant macrophage colony-stimulating factor and recombinant gamma-interferon: toxicity, monocytosis and clinical effects. Cancer Res 1994; 54: 4084-90
101. Bukowski RM, Budd GT, Gibbons JA, et al, Phase 1 trial of subcutaneous recombinant macrophage colony-stimulating factor: clinical and immunomodulatory effects. J Clin Oncol 1994; 12:97-106
102. Zamkoff KW, Hudson JG, Groves ES, et al. A phase 1 trial of recombinant human macrophage colony-stimulating factor by rapid intravenous infusion in patients with refractory malignancy. J Immunother 1992: II: 103-10
103. Redman BG, Flaherty L, ChouTH. etal. Phase I trial of recombinant macrophage colony-stimulating factor by rapid intravenous infusion in patients with cancer. J Immunother 1992; 12:50-4
104. Hennemann B, Meerpohl HG, Oskam R. et al. A phase I trial of intraperitoneally-administered recombinant macrophage colony stimulating factor (rM-CSF) in cancer patients. Onkologie 1991; 14 Suppl. 2:65
105. Lopez AF, Williamson DJ, Gamble JR, et al. Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival. J Clin Invest 1986: 78: 1220-8
106. Smith PD, Lamerson CL. Wong HL. et al. Granulocyte-macrophage colony-stimulating factor stimulates human monocyte accessory cell function. J linmunol 1990; 144: 3829-34
107. Grabstein KH, Urdal DL, Tushinski RJ, et al, Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 1986; 232: 506-8
108. Chachoua A, Oratz R, Hoogmoed R, et al, Monocyte activation following systemic administration of granulocyte-macrophage colony-stimulating factor. J Immunother Emphasis Tumor Immunol 1994; 15: 217-24
109. Ragnhammar P, Fagerberg J, Frodin JE, et al, Effect of monoclonal antibody 17-1 A and GM-CSF in patients with advanced colorectal carcinoma - long-lasting, complete remissions can be induced. Int J Cancer 1993:53: 751-8
110. Chachoua A, Oratz R, Liebes L. et al. Phase Ib trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma. J Immunother Emphasis Tumor Immunol 1994: 16: 132-41
111. Wiltschke C, Krainer M. Wagner A, et al. Influence of in vivo administration of GM-CSF and G-CSF on monocyte cytotoxieity. Exp Hematol 1995; 23: 402-6
112. Scarffe JH, Emerging clinical uses for GM-CSF. Eur J Cancer 27; 1991: 1493-504
113. Herrmann F, Schulz G, Lindemann A. et al. Hematopoietic responses in patients with advanced malignancies treated with recombinant human granulocyte-macrophage colony-stimulating factor. J Clin Oncol 1989; 7: 159-67
114. Schwanz GK, Collins JJ, Galazka A, ei al. Phase I study of subcutaneously administered bacterially-synthesised recombinant human granulocyte-macrophage colony-stimulating factor. Eur J Cancer 1992; 28: 470-3
115. Bartholeyns J, Lombard Y, Dumont S, et al, Immunotherapy of cancer: experimental approach with activated macrophages proliferating in culture. Cancer Detect Prev 1988; 12: 413-20
116. Chokri M, Freudenberg M, Galanos C, et al. Antitumoral effects of lipopolysaccharides. tumor necrosis factor, interferon and activated macrophages: synergism and tissue distribution. Anticancer Res 1989; 9: 1185-90
117. Chakraborty NO, Okino T, Stabach P. et al. Adoptive transfer of activated human autologous macrophages results in regression of transplanted human melanoma cells in seid mice. In Vivo 1991: 5: 609-14
118. Stevenson HG, Keenan AM, Woodhouse C, el al. Fate of IFNgamma activated killer blood monocytes adoptively transferred into the abdominal cavity of patients with peritoneal carcinoma. Cancer Res 1987; 47: 6100-3
119. Andreesen R, Picht J, Löhr GW. Primary cultures of human blood-born macrophages grown on hydrophobic teflon membranes. J Immunol Methods 1983; 56: 295-304
120. Brugger W, Scheibenbogen C, Krause S, et al. Large scale production of human tumor cytotoxic macrophages grown from blood monocytes for the use in adoptive immunotherapy trials. Cancer Detect Prevent 1991; 15:407-12
121. Andreesen R, Scheibenbogen C, Krause S, et al, Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy. Cancer Res 1990; 50: 7450-6
122. Andreesen R, Hennemann B, Adoptive immunotherapy with autologous macrophages: current status and future perspectives. Pathobiology 1991; 59: 259-63
123. Faradji A, Bohbot A, Schmitt-Goguel M, et al. Phase I trial of intravenous infusion of ex-vivo-activated autologous bloodderived macrophages in patients with non-small-cell lung cancer: toxicity and immunomodulatory effects. Cancer Immunol Immunother 1991: 33: 319-26
124. Faradji A, Bohbot A, Schmitt Goguel M, et al. Aphere.siselutriation program for adoptive immunotherapy with autologous activated monocytes in cancer patients. Int J Artif Organs 1991: 14:304-12
125. Lopez M, Fechtenbaum J. David B, et al. Adoptive immunotherapy with activated macrophages grown in vitro from blood monocytes in cancer patients: a pilot study. J Immunother 1992; 11: 209-17
126. Hennemann B, Scheibenbogen C, Schumichen C, et al. Intrahepatic adoptive immunotherapy with autologous tumor cytotoxic macrophages in patients with cancer. J Immunother 1995;18: 19-27
127. Takeda T, Kobyashi T, Monden T, et al. The effect of local immunotherapy for breast cancer using a mixture of OK-432 and fibrinogen supplemented with activated macrophages. Biotherapy 1993; 7: 47-54
128. Dorsch M, Hock H, Kunzendorf U, et al. Macrophage colonystimulating factor gene transfer into tumor cells induces macrophage infiltration but not tumor suppression. Eur J Immunol 1993; 23: 186-90
129. Botta/zi B, Walter S. Govoni D. et al. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth and susceptibility to IL-2 therapy of a murine melanoma. J Immunol 1992; 148: 1280-5
130. Walter S, Bottazzi B, Govoni D, et al. Macrophage infiltration and growth of sarcoma clones expressing different amounts of monocyte chemotactic protein/JE. Int J Cancer 1991; 49: 431-5
131. Heike Y, Sone S, Yano S, et al, M-CSF gene transduction in multidrug-resistant human cancer cells to enhance anti-Pglycoprotein antibody-dependent macrophage mediated cytotoxicity. Int J Cancer 1993; 54: 851-7
132. Dranoff G, Jaffe E, Lazenby A, et al, Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent specific and long-lasting anti-tumor immunity. Proc Natl Acad Sei USA 1993; 90: 3539-43
133. Blankenstein T, Qin Z, Überla K, et al, Tumor suppression of tumor cell targeted tumor necrosis factor ct gene transfer. JExpMed 1991; 173: 1047-52
134. Lollini PL, Bosco MC, Cavallo F, et al, Inhibition of tumor growth and enhancement of metastasis after transfection of the gamma-IFN gene. Im J Cancer 1993; 55: 320-9
135. Haddada H, Lopez M, Martinache C, et al, Efficient adenovirusmediated gene transfer into human blood monocyte-derived macrophages. Biochem Biophys Res Commun 1993; 195: 1174-83